Pulmatrix Reports Q2 Loss, Cash Down to $2.2M; Merger with Eos SENOLYTIX on Track for Q3 Close

summarizeSummary

Pulmatrix reported a Q2 net loss of $1.04 million with cash down to $2.2 million, while confirming the S-4 for its reverse merger with Eos SENOLYTIX was filed and amended, with closing expected in Q3 2026.

check_boxKey Events · Earnings and Guidance · PULM

• Q2 Net Loss of $1.04M

  Net loss was $1.036 million for Q2 2026, an improvement from $1.549 million in Q2 2025, driven by lower G&A expenses.

• Cash Drops to $2.2M

  Cash and cash equivalents fell to $2.2 million as of June 30, 2026, from $4.1 million at December 31, 2025, with an additional $0.7 million in restricted cash available after merger close.

• Going Concern Warning Reiterated

  Financial statements were prepared assuming the company will continue as a going concern, but management expects cash to fund operations through the anticipated Q3 2026 merger close.

• S-4 Filed and Amended

  The Form S-4 for the reverse merger with Eos SENOLYTIX was filed July 9, 2026 and amended August 3, 2026; closing is anticipated in Q3 2026.

auto_awesomeAnalysis · PULM · Life Sciences

Pulmatrix's Q2 results show a shrinking cash position — $2.2 million as of June 30, down from $4.1 million at year-end — while the company continues to burn roughly $1 million per quarter. The going concern warning remains, but management states cash is sufficient to reach the anticipated Q3 merger close with Eos SENOLYTIX. The filing also confirms the S-4 registration statement was filed July 9 and amended August 3, moving the reverse merger closer to completion. For legacy shareholders, the merger will leave them with only 6% of the combined company, making the successful close critical to avoiding a cash shortfall.